MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 319992 | Name: Sugammadex sodium
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sugammadex sodium is an agent for reversal of neuromuscular blockade by the agent rocuronium in general anaesthesia. It is the first selective relaxant binding agent (SRBA). Sugammadex is a modified γ-cyclodextrin, with a lipophilic core and a hydrophilic periphery. This gamma cyclodextrin has been modified from its natural state by placing eight carboxyl thio ether groups at the sixth carbon positions. These extensions extend the cavity size allowing greater encapsulation of the rocuronium molecule.

Chemical Structure

Sugammadex sodium
Sugammadex sodium
CAS#343306-79-6 (sodium)

Theoretical Analysis

MedKoo Cat#: 319992

Name: Sugammadex sodium

CAS#: 343306-79-6 (sodium)

Chemical Formula: C72H104Na8O48S8

Exact Mass: 0.0000

Molecular Weight: 2177.97

Elemental Analysis: C, 39.71; H, 4.81; Na, 8.44; O, 35.26; S, 11.78

Price and Availability

Size Price Availability Quantity
10mg USD 90.00 Ready to ship
25mg USD 150.00 Ready to ship
50mg USD 225.00 Ready to ship
100mg USD 385.00 Ready to ship
200mg USD 650.00 Ready to ship
500mg USD 1,350.00 Ready to ship
1g USD 2,350.00 Ready to ship
2g USD 4,250.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
343306-71-8 (free form) 343306-79-6 (sodium)
Synonym
Org25969; Org-25969; Org 25969; 361LPM2T56; Sugammadex; trade name: Bridion. Sugammadex sodium
IUPAC/Chemical Name
6A,6B,6C,6D,6E,6F,6G,6H-octakis-S-(2-Carboxyethyl)-6A,6B,6C,6D,6E,6F,6G,6H-octathio-γ-cyclodextrin sodium salt
InChi Key
KMGKABOMYQLLDJ-LHCKBTHCSA-F
InChi Code
InChI=1S/C72H112O48S8.8Na/c73-33(74)1-9-121-17-25-57-41(89)49(97)65(105-25)114-58-26(18-122-10-2-34(75)76)107-67(51(99)43(58)91)116-60-28(20-124-12-4-36(79)80)109-69(53(101)45(60)93)118-62-30(22-126-14-6-38(83)84)111-71(55(103)47(62)95)120-64-32(24-128-16-8-40(87)88)112-72(56(104)48(64)96)119-63-31(23-127-15-7-39(85)86)110-70(54(102)46(63)94)117-61-29(21-125-13-5-37(81)82)108-68(52(100)44(61)92)115-59-27(19-123-11-3-35(77)78)106-66(113-57)50(98)42(59)90;;;;;;;;/h25-32,41-72,89-104H,1-24H2,(H,73,74)(H,75,76)(H,77,78)(H,79,80)(H,81,82)(H,83,84)(H,85,86)(H,87,88);;;;;;;;/q;8*+1/p-8/t25?,26?,27?,28?,29?,30?,31?,32?,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,68+,69+,70+,71+,72?;;;;;;;;/m0......../s1
SMILES Code
O[C@H]1[C@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](O)[C@H](O[C@@H]4[C@@H](O)[C@H](O)[C@H](O[C@@H]5[C@@H](O)[C@H](O)[C@H](O6)C(CSCCC(O[Na])=O)O5)C(CSCCC(O[Na])=O)O4)C(CSCCC(O[Na])=O)O3)C(CSCCC(O[Na])=O)O2)C(CSCCC(O[Na])=O)O[C@@H]1O[C@H]7[C@@H](O)[C@H](O)[C@@H](O[C@H]8[C@@H](O)[C@H](O)[C@@H](O[C@H]9[C@@H](O)[C@H](O)C6OC9CSCCC(O[Na])=O)OC8CSCCC(O[Na])=O)OC7CSCCC(O[Na])=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in water
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS@ 343306-71-8 (free form); 343306-79-6 (sodium salt)
Biological target:
Sugammadex is a selective relaxant binding agent for complexing aminosteroid nonpolarizing neuromuscular blockers.
In vitro activity:
Sugammadex has protective and antioxidant properties on cytotoxicity and could be an effective supplement for neurodegenerative diseases such as Alzheimer and Parkinson diseases. Sugammadex at concentrations of 50 and 100 μg/mL significantly enhanced the cell viability in C6 glioma cells after the cytotoxicity induced by glutamate. Sugammadex considerably decreased the levels of nNOS NO and TOS and the number of apoptotic cells and increased the level of TAS. Reference: Fundam Clin Pharmacol. 2023 Aug;37(4):786-793. https://pubmed.ncbi.nlm.nih.gov/36880372/
In vivo activity:
In early chick embryos, sugammadex exposure correlated with decreased embryo size, somite counts, and increased Caspase-3 H-Score, suggesting developmental delays and higher neural tube defect incidence. These findings indicate that sugammadex crossing the placenta may disrupt embryonic development, with effects increasing dose-dependently. Reference: Microsc Res Tech. 2024 Mar;87(3):506-515. https://pubmed.ncbi.nlm.nih.gov/37933747/
Solvent mg/mL mM
Solubility
DMSO 2.5 1.15
DMSO:PBS (pH 7.2) (1:30) 0.0 0.01
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 2,177.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Dirik H, Joha Z. Investigation of the effect of sugammadex on glutamate-induced neurotoxicity in C6 cell line and the roles played by nitric oxide and oxidative stress pathways. Fundam Clin Pharmacol. 2023 Aug;37(4):786-793. doi: 10.1111/fcp.12890. Epub 2023 Mar 14. PMID: 36880372. 2. Fliszár-Nyúl E, Csepregi R, Benkovics G, Szente L, Poór M. Testing the Protective Effects of Sulfobutylether-Βeta-Cyclodextrin (SBECD) and Sugammadex against Chlorpromazine-Induced Acute Toxicity in SH-SY5Y Cell Line and in NMRI Mice. Pharmaceutics. 2022 Sep 7;14(9):1888. doi: 10.3390/pharmaceutics14091888. PMID: 36145637; PMCID: PMC9504268. 3. Büyükerkmen E, Atay E, Firat F, Yüksek A, Bilir A, Albaş Kurt G, Saritaş A. Effect of sugammadex administration on neural tube development in 48-h chick embryos. Microsc Res Tech. 2024 Mar;87(3):506-515. doi: 10.1002/jemt.24452. Epub 2023 Nov 7. PMID: 37933747. 4. Park HY, Choi HR, Kim YB, Oh SK, Kim T, Yang HS, In J. Chronic exposure to dexamethasone may not affect sugammadex reversal of rocuronium-induced neuromuscular blockade: an in vivo study on rats. Anesth Pain Med (Seoul). 2023 Jul;18(3):275-283. doi: 10.17085/apm.23021. Epub 2023 Jul 14. PMID: 37468197; PMCID: PMC10410550.
In vitro protocol:
1. Dirik H, Joha Z. Investigation of the effect of sugammadex on glutamate-induced neurotoxicity in C6 cell line and the roles played by nitric oxide and oxidative stress pathways. Fundam Clin Pharmacol. 2023 Aug;37(4):786-793. doi: 10.1111/fcp.12890. Epub 2023 Mar 14. PMID: 36880372. 2. Fliszár-Nyúl E, Csepregi R, Benkovics G, Szente L, Poór M. Testing the Protective Effects of Sulfobutylether-Βeta-Cyclodextrin (SBECD) and Sugammadex against Chlorpromazine-Induced Acute Toxicity in SH-SY5Y Cell Line and in NMRI Mice. Pharmaceutics. 2022 Sep 7;14(9):1888. doi: 10.3390/pharmaceutics14091888. PMID: 36145637; PMCID: PMC9504268.
In vivo protocol:
1. Büyükerkmen E, Atay E, Firat F, Yüksek A, Bilir A, Albaş Kurt G, Saritaş A. Effect of sugammadex administration on neural tube development in 48-h chick embryos. Microsc Res Tech. 2024 Mar;87(3):506-515. doi: 10.1002/jemt.24452. Epub 2023 Nov 7. PMID: 37933747. 2. Park HY, Choi HR, Kim YB, Oh SK, Kim T, Yang HS, In J. Chronic exposure to dexamethasone may not affect sugammadex reversal of rocuronium-induced neuromuscular blockade: an in vivo study on rats. Anesth Pain Med (Seoul). 2023 Jul;18(3):275-283. doi: 10.17085/apm.23021. Epub 2023 Jul 14. PMID: 37468197; PMCID: PMC10410550.
1: Kranendijk M, Waterval JC, Somsen GW, de Jong GJ. Evaluation of the sensitivity of miniaturized liquid chromatography-electrospray ionization-mass spectrometry for pharmaceutical analysis. J Sep Sci. 2005 Sep;28(14):1796-802. doi: 10.1002/jssc.200500203. PMID: 16224975. 2: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Sep;29(7):467-509. PMID: 17982511. 3: Molecule of the month. Sugammadex sodium. Drug News Perspect. 2007 Nov;20(9):591-2. PMID: 18176664. 4: Tomillero A, Moral MA. Gateways to clinical trials. December 2008. Methods Find Exp Clin Pharmacol. 2008 Dec;30(10):761-82. PMID: 19271026. 5: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Jan-Feb;31(1):47-57. PMID: 19357798. 6: Welliver M, Cheek D. An update on sugammadex sodium. AANA J. 2009 Jun;77(3):219-28. PMID: 19645172. 7: Welliver M, McDonough J, Kalynych N, Redfern R. Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent. Drug Des Devel Ther. 2009 Feb 6;2:49-59. doi: 10.2147/dddt.s2757. PMID: 19920893; PMCID: PMC2761174. 8: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Jun;32(5):331-88. doi: 10.1358/mf.2010.32.5.1520420. PMID: 20664824. 9: Maeda T, Enomoto T, Kamiyama Y, Inada E. [Anesthetic management for electroconvulsive therapy using rocuronium bromide and sugammadex sodium in a patient with suspected malignant syndrome]. Masui. 2011 Dec;60(12):1384-6. Japanese. PMID: 22256579. 10: Llauradó S, Sabaté A, Ferreres E, Camprubí I, Cabrera A. Postoperative respiratory outcomes in laparoscopic bariatric surgery: comparison of a prospective group of patients whose neuromuscular blockade was reverted with sugammadex and a historical one reverted with neostigmine. Rev Esp Anestesiol Reanim. 2014 Dec;61(10):565-70. doi: 10.1016/j.redar.2013.11.009. Epub 2014 Jan 9. PMID: 24411663. 11: Welliver M, Cheek D, Osterbrink J, McDonough J. Worldwide experience with sugammadex sodium: implications for the United States. AANA J. 2015 Apr;83(2):107-15. PMID: 26016169. 12: Seno H, Komasawa N, Hasegawa Y, Kusaka Y, Umegaki O, Minami T. [Development of Takotsubo Cardiomyopathy during Recovery from General Anesthesia: A Case Report]. Masui. 2015 Aug;64(8):826-9. Japanese. PMID: 26442416. 13: Hussar DA, Cheeseman RS 2nd. Lifitegrast, Bezlotoxumab, and Sugammadex sodium. J Am Pharm Assoc (2003). 2017 Mar-Apr;57(2):284-287. doi: 10.1016/j.japh.2017.02.004. PMID: 28285777. 14: Kim NY, Koh JC, Lee KY, Kim SS, Hong JH, Nam HJ, Bai SJ. Influence of reversal of neuromuscular blockade with sugammadex or neostigmine on postoperative quality of recovery following a single bolus dose of rocuronium: A prospective, randomized, double-blinded, controlled study. J Clin Anesth. 2019 Nov;57:97-102. doi: 10.1016/j.jclinane.2019.02.014. Epub 2019 Mar 30. PMID: 30939422. 15: Donmez T, Erdem VM, Sunamak O, Ozcevik H. THYROID SURGERY, IONM AND SUGAMMADEX SODIUM RELATIONSHIPS: BENEFITS IN SUGAMMADEX SODIUM USE FOR IONM. Acta Endocrinol (Buchar). 2019 Oct-Dec;15(4):454-459. doi: 10.4183/aeb.2019.454. PMID: 32377242; PMCID: PMC7200106. 16: Stemhagen A, Bhangu P, Zhong W, Julian M, Deutsch G, Koro C. Knowledge and Understanding of the Safety and Efficacy Aspects of BRIDION® Among Canadian Anesthesiologists. Drugs Real World Outcomes. 2020 Sep;7(3):251-256. doi: 10.1007/s40801-020-00200-z. PMID: 32451965; PMCID: PMC7392970. 17: Zhuang T, Chen Y, Xu J, Qi Z, Ye J, Xu C, Du W, Liu B, Zhang G. Isolation, structural characterization and quality control strategy of an unknown process- related impurity in sugammadex sodium. J Pharm Biomed Anal. 2021 Jun 5;200:114072. doi: 10.1016/j.jpba.2021.114072. Epub 2021 Apr 15. PMID: 33866296. 18: Wang Z, Li L, Xin L, Wu S, Liu Y, Liao S, Ma P, Sun J, Huang L. Special Application of ms/ms Method on Determination of Regiochemistry of Sugammadex Series Compounds: Synthesis, Isolation and Structural Characterization for Two Potential Oxidative Impurities in Sugammadex Sodium Finished Pharmaceutical Product. J Pharm Sci. 2022 Feb;111(2):306-313. doi: 10.1016/j.xphs.2021.08.027. Epub 2021 Aug 29. PMID: 34469750. 19: Mohanraj SKP, Tulasi R, Subramanian VC, Dandu BSR, Guvvala V, Kota SR. A study on structural characterization of potential impurities of Sugammadex sodium using LC/ESI/QTOF/MS/MS and NMR. J Pharm Biomed Anal. 2022 Jan 5;207:114419. doi: 10.1016/j.jpba.2021.114419. Epub 2021 Oct 13. PMID: 34710726. 20: Zhou S, Hu H, Ru J. Efficacy and safety of sugammadex sodium in reversing rocuronium-induced neuromuscular blockade in children: An updated systematic review and meta-analysis. Heliyon. 2023 Jul 15;9(8):e18356. doi: 10.1016/j.heliyon.2023.e18356. PMID: 37520945; PMCID: PMC10374931.